Peritoneal tuberculosis simulating advanced ovarian carcinoma: is clinical impression sufficient to administer neoadjuvant chemotherapy for advanced ovarian cancer?

Abstract.   Gurbuz A, Karateke A, Kabaca C, Kir G, Cetingoz E. Peritoneal tuberculosis simulating advanced ovarian carcinoma: is clinical impression sufficient to administer neoadjuvant chemotherapy for advanced ovarian cancer? Int J Gynecol Cancer 2006; 16(Suppl. 1): 307–312.
Peritoneal tuberculosis mimics advanced ovarian cancer because of the similarities in clinical signs and symptoms such as ascites, pelvic and abdominal pain and mass, and elevation of serum CA125 level. We have presented four cases of peritoneal tuberculosis that underwent exploratory laparotomy for suspected advanced ovarian cancer during a 3-year period. Definitive diagnosis of tuberculosis was performed at laparotomy in all the cases. The frozen-section analysis seems to be the gold standard in the differential diagnosis. In view of these data, clinical diagnosis of advanced ovarian cancer is not sufficient for administering neoadjuvant chemotherapy. Cytologic or pathologic findings must be consistent with ovarian cancer for candidates who are being considered for neoadjuvant chemotherapy.     

人血清胰岛素抗体、猪胰岛素原抗体和胰多肽抗体的放射免疫检测法

作者用自制的[~(125)I]标记激素,参考国外经验,建立了人血清胰岛素抗体、猪胰岛素原抗体和胰多肽抗体等三种放射免疫检测法,并对方法的主要实验条件进行了优选,对方法的质量控制参数作了验证。结果发现:在使用国产胰岛素的糖尿病人血清中,三种抗体的检出率分别为90.8％、48.3％和36.5％;抗体特异性结合值分别为21.2±17.4％、41.8±27.4％和25.6±28.4;而正常人和糖尿病人未用胰岛素者全部为阴性,显示国产胰岛素具有明显的免疫原性。     

Immunohistochemical Study of Colorectal Polyps with Antibodies against CEA,CA19-9, CA125, CA15-3 (DF3), PCNA and p53

Abstract: We analyzed the expression of CEA, CA19-9, CA125, CA15-3 (DF3), PCNA and p53 immunohistochemically in 14 tissue specimens of mucosal cancers in adenoma, seven tubulovillous adenoma specimens, and 16 tubular adenoma specimens. The rates of positive staining for mucosal cancer in adenoma, tubulovillous adenoma and tubular adenoma specimens, respectively, were: for CEA: 100%, 85.7% and 75%; for CA19-9: 71.4%, 71.4% and 56.2%; for CA125:0%, 0% and 0%;for CA15-3 (DF3): 64.3 %, 0% and 0 %; for PCNA: 100%, 88.9% and 56.2%; and for p53: 35.7%, 0% and 0% . The results suggest that the expressions of CEA, CA19-9, CA15-3 (DF3), PCNA and p53 are related to colorectal tumorigenesis. None of the specimens studied showed staining for CA125, suggesting that CA125 is not involved in the early stages of colorectal carcinogenesis. There was no significant difference in the rates of positive staining for CEA and CA19-9 among mucosal cancer in adenoma, tubular adenoma and tubulovillous adenoma specimens. However, the rates of positive staining for PCNA and p53 were significantly higher in mucosal cancer in adenoma specimens than for tubular adenoma specimens (p<0.05), and the rate of CA15-3 (DF3) positive staining was significantly higher for mucosal cancer in adenoma than for tubulovillous adenoma (p<0.01) and tubular adenoma (p< 0.001) specimens. Therefore, the CA15-3 (DF3) antigen is an immunohistochemical marker for colorectal carcinomas. The present results suggest that CA15-3 (DF3), PCNA and p53 play important roles in the genesis of colorectal adenomas.     

放射性碘对大鼠致癌效应的研究

对雄性Wisiaf大鼠腹腔1次注射碘-13l, 注入活度分别为0.59×10⁴Bq,2.37×10⁴Bq, 4.34×10⁴Bq, 8.23×10⁴Bq, 碘-125注入活度分别为3.7×10⁴Bq, 7.4×10⁴Bq, 14.8×10⁴Bq, 22.2×10⁴Bq.碘-131诱发肿痛实际注入活度在2.37×10⁴Bq以下,碘-125的为7.4×10⁴以下.诱发的肿瘤以甲状腺肿瘤为主,其次为垂体肿瘤.     

白蛋白微球作为肝靶向给药载体的研究

用均匀设计方法和计算机技术筛选了乳化化学交联法制备白蛋白微球的六个因素,十二个水平。优化出最佳制备工艺,制备了平均粒径0.41～0.47μm的白蛋白微球。将此工艺制备的¹²⁵I-白蛋白微球做动物体内研究,结果表明微球iv后主要浓集在肝脏,可达注入总剂量的68%,此微球在靶组织肝脏的变化规律可用二室模型契合。     

~(125)碘-绒毛膜促性腺激素的电泳纯化及分析

标记抗原在贮存过程中,由于受幅射分解和脱碘影响而使免疫活性和生物活性降低。我们对自制的~(125)碘-绒毛膜促性腺激素进行了实验观察。结果显示:贮存1月后,其免疫活性和生物活性分别降低了33.1％和44.0％;经电泳纯化后的标记物的免疫活性和生物活性明显提高,分别达到了最初的90.5％和95.3％。     

放射性125I粒子组织间植入或联合放化疗治疗复发直肠癌

目的探讨超声或CT引导下放射性125I粒子组织间植入治疗复发直肠癌的技术可行性、近期疗效和副反应.方法 15例直肠癌术后盆腔复发患者,女4例,男11例.硬膜外麻醉,2例经阴道超声引导,13例CT引导,行放射性125I粒子植入术.肿瘤匹配周边剂量为90～110 Gy,每颗粒子活度为0.50～0.70 mCi,植入33～70颗.术后24～48 h拍胸、盆腔X线片了解粒子是否发生移位.术后6例加三维适形放疗,4～6野/次,200～300 cGy/次,5次/周,总剂量为4 500～5 000 cGy,间隔4周.2例粒子治疗后加草酸铂、5-氟尿嘧啶和四氢叶酸化疗1个周期,随访3～15个月,根据CT扫描结果判断肿瘤大小. 结果术后平均7天疼痛缓解,其中12例完全缓解,2例部分缓解,1例无变化,有效率93%(14/15).9例肿瘤完全缓解,2例部分缓解,4例局部进展,局部控制率73%(11/15).2例术后6个月和12个月时死于肺转移.1例1颗粒子移位至盆壁,随访12个月无症状.无治疗相关并发症和副作用发生. 结论经超声或CT引导放射性125I粒子植入治疗复发直肠癌具有安全、微创、并发症发生率低和疗效肯定等优势,粒子治疗后应配合外放疗和全身化疗,有望进一步提高疗效.     

复方葡萄籽提取物对乙醇及四氯化碳肝损伤的影响

目的：探讨复方葡萄籽提取物（GSE）对化学性肝损伤的预防和治疗作用。方法：用小鼠建造四氯化碳肝损伤和乙醇肝损伤模型，观察乙醇灌胃前预先给予复方GSE及乙醇或四氯化碳灌胃后再给予复方GSE后小鼠血清谷丙转氨酶（ALT），肝细胞超氧化物歧化酶（SOD）、谷光甘肽（GSH）、丙二醛（MDA）。结果：预先给予GSE可增强SOD活性，防止乙醇导致的肝GSH减少，有效降低小鼠血清ALT和肝细胞MDA上升程度，在乙醇或四氯化碳灌胃后再给予复方GSE，也可降低小鼠血清中ALT和肝细胞脂质过氧化产物。结论：复方GSE对乙醇肝损伤有预防和治疗作用。对四氯化碳肝损伤也有一定治疗作用。     

系统性红斑狼疮女性患者血清CA125,CA199化学发光法测定的临床应用

目的 :探讨系统性红斑狼疮 (SLE)女性患者血清肿瘤标志物CA12 5 ,CA199含量变化及临床意义。方法 :用化学发光法测定 30例正常女性和 38例SLE女性患者血清中CA12 5 ,CA199含量。结果 :正常组CA12 5含量为 11.14± 6 .4 8U/ml,CA199含量为 3.75± 2 .89U/ml;SLE组CA12 5 ,CA199分别为 2 2 .5 6± 2 0 .4 6U/ml,9.5 7± 9.34U/ml。SLE患者CA12 5 ,CA199阳性率分别为 2 1.1% ,7.89%。结论 :SLE患者血清CAl2 5 ,CA199含量较正常组增高 (P <0 .0 5 )。CA12 5 ,CA199在SLE女性患者中可出现阳性 ,对临床诊断SLE有一定价值。     

多色杀生固定法对保持中药原植物色泽的实验研究

目的：应用多色杀生固定法对42种不同色泽果实、种子的植物浸制标本制作的实验研究。结果：多色杀生固定液能较理想地保存42种实验材料、叶、果实、种子、果肉、花序等的原有色泽。该研究为浸制标本的制作开辟了广阔的发展前景。